Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study

CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153

Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research